Education
About Us
Working with TipRanks
Follow Us
Femasys (FEMY)
NASDAQ:FEMY
FEMY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.86 - $1.84
Previous CloseN/A
Volume25.00K
Average Volume (3M)633.40K
Market Cap
$30.57M
Enterprise Value$24.30M
Total Cash (Recent Filing)-$7.41M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.36
Next Earnings
May 08, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding22,898,468
10 Day Avg. Volume998,614
30 Day Avg. Volume633,402
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)29.06
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit35.13
Enterprise Value/Ebitda-1.53
Forecast
1Y Price Target
$9.00Price Target Upside571.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPositive data from three initial clinical studies were highlighted in a peer-reviewed publication, demonstrating a 0% pregnancy rate and strong safety over a 5-year period, with high satisfaction from both patients and practitioners.
Commercial ExpansionNew partnership with CNY Fertility expands commercial footprint for FemaSeed, increasing revenue potential.
Regulatory ApprovalFemBloc received EU approval, and the company announced partnerships in Spain, indicating international market expansion.
Bears Say
Procedure AlterationsSeveral alterations were made to the FemBloc procedure with several unintended pregnancies occurring, which are being evaluated in the ongoing pivotal study.
---
Ownership Overview
5.39%
Insiders
4.45% Mutual Funds
4.52% Other Institutional Investors
82.04% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
FEMY FAQ
What was Femasys’s price range in the past 12 months?
Femasys lowest stock price was $0.86 and its highest was $1.84 in the past 12 months.
What is Femasys’s market cap?
Femasys’s market cap is $30.57M.
When is Femasys’s upcoming earnings report date?
Femasys’s upcoming earnings report date is May 08, 2025 which is in 39 days.
How were Femasys’s earnings last quarter?
Femasys released its earnings results on Mar 27, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.045.
Is Femasys overvalued?
According to Wall Street analysts Femasys’s price is currently Undervalued.
Does Femasys pay dividends?
Femasys does not currently pay dividends.
What is Femasys’s EPS estimate?
Femasys’s EPS estimate is -0.22.
How many shares outstanding does Femasys have?
Femasys has 22,898,468 shares outstanding.
What happened to Femasys’s price movement after its last earnings report?
Femasys reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went down -11.842%.
Which hedge fund is a major shareholder of Femasys?
Currently, no hedge funds are holding shares in FEMY
---
Femasys Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (571.64% Upside)
$9.00 (571.64% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.18%
12-Months-Change
Fundamentals
Return on Equity
-182.18%
Trailing 12-Months
Asset Growth
-55.16%
Trailing 12-Months
Company Description
Femasys
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
---
FEMY Stock 12 Month Forecast
Average Price Target
$9.00
▲(571.64% Upside)
Technical Analysis
Best Analysts Covering FEMY
1 Year
1 Year Success Rate
9/14 ratings generated profit
1 Year Average Return
+24.34%
reiterated a buy rating 5 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 64.29% of your transactions generating a profit, with an average return of +24.34% per trade.
---